Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma

Oncoimmunology. 2013 May 1;2(5):e24320. doi: 10.4161/onci.24320.


The combination of BRAF-targeted agents with immune checkpoint inhibitors represents a recent advance in the treatment of melanoma, even though each of these therapeutic approaches alone has specific limitations. Increasing evidence suggests indeed the existence of a synergistic interaction between these therapeutic modalities.

Keywords: BRAF; PDL1; checkpoint blockade; immunotherapy; melanoma.